See also this year's filing and all EDGAR filings for this company.
PDF Report 0000744218_2012_Celldex_Therapeutics_Inc.pdf
Logs
| info | NetIncome node detected by tax heuristic | input.sec.calculation_linkbase.edgar_model_mapping | {'net_inc_node': 'NetIncomeLossAvailableToCommonStockholdersBasic'} |
| info | Ambiguous roles for statement | input.sec.calculation_linkbase.expand_agg | {'statement': 'operations', 'valid_roles': {'0020 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS': 15, '0021 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS CALC 2': 3}} |
| info | Added remainder_ComprehensiveNetIncome directly from 10K | industry.us_generic | {} |
Graph
Absolute values for 0000744218, Celldex Therapeutics Inc
| xvar | xval | |
|---|---|---|
| 0 | LiabilitiesNoncurrent | 5,966,000 |
| 1 | LiabilitiesCurrent | 14,298,000 |
| 2 | remainder_Liabilities | 9,008,000 |
| 3 | AssetsCurrent | 54,684,000 |
| 4 | AssetsNoncurrent | 329,000 |
| 5 | PropertyPlantAndEquipmentNet | 9,093,000 |
| 6 | Goodwill | 33,888,000 |
| 7 | remainder_Assets | 0 |
| 8 | GeneralAndAdministrativeExpense | 9,243,000 |
| 9 | ResearchAndDevelopmentExpense | 32,439,000 |
| 10 | remainder_Expenses | 12,778,000 |
| 11 | remainder_Revenues | 9,265,000 |
| 12 | remainder_NetIncome | 396,000 |
| 13 | remainder_ComprehensiveNetIncome | -99,000 |
| yvar | yval | |
|---|---|---|
| 0 | Liabilities | 29,272,000 |
| 1 | Assets | 97,994,000 |
| 2 | Expenses | 54,460,000 |
| 3 | Revenues | 9,265,000 |
| 4 | StockholdersEquity | 68,722,000 |
| 5 | NetIncome | -44,799,000 |
| 6 | ComprehensiveNetIncome | -44,848,500 |
| 7 | BaseVar | 95,743,000 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 0.775 |
| 9 | EconomicCapitalRatio | 1.52 |
Edgar->Model Mapping
Feature Distribution
